Lack of awareness among the populace is a major problem leading to health problems that can be easily avoided through proper medical adherence.
Increasing geriatric population and rise in adoption of enteral feeding devices will drive the overall immunotherapy drugs market
Crohn’s disease is a form of inflammatory bowel disease (IBD) that refers to a chronic inflammatory condition of the gastrointestinal tract causing inflammation in the digestive tract.
According to a study published in the British Journal of Dermatology in 2015, 9.4% of global population was estimated to be affected by acne.
Cancer is the disease in which cell grows abnormally and may cause a tumor.
High funding for research and development and clinical trials drugs to boost the tuberculosis drugs market.
Based on this technique, three types of blood irradiation are available in the market i.e. intravenous laser blood irradiation, transcutaneous laser blood irradiation, and extracorporeal blood irradiation.
Increasing number of hip and knee replacement surgeries are augmenting rivaroxaban market growth
Newborn screening tests look for developmental, metabolic, and genetic disorders in infants.
Low investment cost and high accessibility to healthcare facilities are major factors driving growth of the micro-hospitals market
Immune system of haemophilia patients’ produces antibodies called as inhibitors, which acts against the administered therapy.
Point-of-care diagnostic devices and high cost of the wearable biosensor devices are the factors restraining market growth.
Large volume parenteral comes in bag or bottle for intravenous administration and are used for correction of fluid/electrolyte balance, providing nutrition such as dextrose.
The most common types of glaucoma are Primary Open Angle Glaucoma (POAG) and Primary Angle Closure Glaucoma (PACG).
Increasing launches of novel drugs for treatment of drug abuse in market is expected to drive the global drug abuse treatment market growth in near future.
Tissue plasminogen activator is the first and only drug approved by the FDA in 1996 for the treatment of acute ischemic stroke.